Covid19 Clinical Trial - Health After Covid-19 in Tyrol

Status Recruiting

Clinical Trial Summary

The aim of the regional online questionnaire is to better understand the pattern of acute infection and the time of recovery of various symptoms.

Clinical Trial Description

The ongoing COVID-19 pandemic considerably increases the demand for healthcare and raises concerns on longterm disease outcome. Accordingly, to increase the knowledge on recovery from symptoms of acute infection and longterm health effects, a regional COVID-19 online survey on the health-status after infection will be performed. This cross-sectional anonymous online survey is initiated and conducted by an interdisciplinary study team of the Medical University of Innsbruck, Austria. For each participant, demographic characteristics (e.g. age, gender, district affiliation, profession), medical history (presence of comorbidities, medication), diagnosis of COVID-19, symptoms and their duration, treatments and special conditions will be collected. The aim of the survey is to better understand the pattern of acute infection and the time of recovery of various symptoms. The anonymous online survey is open to individuals after COVID-19 infection (proven by SARS-Cov-2 positive PCR or antibody test) over the age of 16 and living in Tyrol (Western-Austria). The survey takes around 30 minutes to complete. ;

Study Design

Related Conditions & MeSH terms

COVID-19

Clinical Trial Details

NCT number	NCT04661462
Study type	Observational
Source	Medical University Innsbruck
Contact	Judith Löffler-Ragg, MD
Phone	++43-512-504-81413
Email	[email protected]
Status	Recruiting
Phase
Start date	September 30, 2020
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05047601` - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection	Phase 3
Recruiting	`NCT04481633` - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection	N/A
Recruiting	`NCT05323760` - Functional Capacity in Patients Post Mild COVID-19	N/A
Active, not recruiting	`NCT04612972` - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru	Phase 3
Completed	`NCT04537949` - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults	Phase 1/Phase 2
Recruiting	`NCT05191394` - IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON ACQUIRED VACCINAL ANTI-SARS-CoV-2 ANTIBODIES.	N/A
Active, not recruiting	`NCT05158816` - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting	`NCT04341506` - Non-contact ECG Sensor System for COVID19
Recruiting	`NCT04512079` - FREEDOM COVID-19 Anticoagulation Strategy	Phase 4
Active, not recruiting	`NCT04384445` - Zofin (Organicell Flow) for Patients With COVID-19	Phase 1/Phase 2
Terminated	`NCT04498273` - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80	Phase 3
Enrolling by invitation	`NCT05089305` - Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection	Phase 2
Recruiting	`NCT04528901` - Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)
Recruiting	`NCT04357990` - Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19	N/A
Active, not recruiting	`NCT04527471` - Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19	Phase 2
Recruiting	`NCT05041907` - Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)	Phase 2
Active, not recruiting	`NCT05022329` - COVID-19 Vaccine Boosters in Patients With CKD	Phase 2/Phase 3
Not yet recruiting	`NCT04990466` - Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.	Phase 2/Phase 3
Recruiting	`NCT05323799` - The Optimising Isolation, Quarantine and Distancing Study for COVID-19 (Optimise)
Not yet recruiting	`NCT04446065` - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers	Phase 2/Phase 3